B cell depletion in infants after intra uterine exposure to immunomodulating chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): A case series and review of the literature

Clinical Immunology Communications Pub Date : 2023-06-22 DOI:10.1016/j.clicom.2023.06.004

Jantien W. Wieringa , Mirjam J. Esser , Jan G.M.C. Damoiseaux , Gertjan A. Driessen , Joyce J.B.C. van Beers

{"title":"B cell depletion in infants after intra uterine exposure to immunomodulating chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): A case series and review of the literature","authors":"Jantien W. Wieringa , Mirjam J. Esser , Jan G.M.C. Damoiseaux , Gertjan A. Driessen , Joyce J.B.C. van Beers","doi":"10.1016/j.clicom.2023.06.004","DOIUrl":null,"url":null,"abstract":"<div><p>The immunomodulating chemotherapeutic drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) have the ablity to pass the placenta during pregnancy and might affect the development of the immune system of exposed infants. In particular rituximab causes a transient and almost complete depletion of CD20 expressing B cells and can remain detectable in the infant several months after birth.</p><p>In this case series we report on the clinical and immunological outcomes of 3 infants exposed to R-CHOP during pregnancy because of maternal B-cell lymphoma and review other cases that have been published. We show that R-CHOP in pregnancy has a profound effect on the immune system in the first year of life, including B-cell lymphopenia, hypogammaglobinemia, neutropenia and decreased response to immunization. Immune monitoring of exposed infants is warranted.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277261342300015X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

The immunomodulating chemotherapeutic drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) have the ablity to pass the placenta during pregnancy and might affect the development of the immune system of exposed infants. In particular rituximab causes a transient and almost complete depletion of CD20 expressing B cells and can remain detectable in the infant several months after birth.

In this case series we report on the clinical and immunological outcomes of 3 infants exposed to R-CHOP during pregnancy because of maternal B-cell lymphoma and review other cases that have been published. We show that R-CHOP in pregnancy has a profound effect on the immune system in the first year of life, including B-cell lymphopenia, hypogammaglobinemia, neutropenia and decreased response to immunization. Immune monitoring of exposed infants is warranted.

查看原文本刊更多论文

子宫内暴露于利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松(R-CHOP)免疫调节化疗后的婴儿B细胞耗竭:病例系列和文献回顾

免疫调节化疗药物利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）具有在妊娠期间通过胎盘的能力，并可能影响暴露婴儿免疫系统的发育。特别是利妥昔单抗引起表达CD20的B细胞的短暂且几乎完全耗竭，并且在婴儿出生几个月后仍然可以检测到。在本系列病例中，我们报告了3例妊娠期因母体B细胞淋巴瘤暴露于R-CHOP的婴儿的临床和免疫结果，并回顾了其他已发表的病例。我们发现，妊娠期的R-CHOP对出生后第一年的免疫系统有着深远的影响，包括B细胞淋巴细胞减少症、低丙种球蛋白血症、中性粒细胞减少症和免疫反应降低。有必要对接触过病毒的婴儿进行免疫监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Immunology Communications

自引率

0.00%

发文量